Statins - Are they potentially useful in rheumatology?;Statyny - Czy okaża̧ siȩ przydatne w reumatologii?

Polskie Archiwum Medycyny Wewnetrznej

Volumn 117, Issue 9, 2007, Pages 420-425

  Bielinska, Aneta ^a   Gluszko, Piotr ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Inflammatory markers; Pleiotropic effect of statins; Rheumatic diseases; Statins

Indexed keywords

ATORVASTATIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ATHEROSCLEROSIS; BIOSYNTHESIS; FRACTURE; HUMAN; INFLAMMATION; OSSIFICATION; OSTEOLYSIS; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; OSTEOPOROSIS; RHEUMATIC DISEASE; TREATMENT OUTCOME;

ARTHRITIS, RHEUMATOID; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; OSTEOPOROSIS; PYRROLES; RHEUMATIC DISEASES; SIMVASTATIN; TREATMENT OUTCOME;

EID: 36549044366     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.206     Document Type: Review

References (43)

1. Lubiszewska B, Rużyłło W. Statyny - panacea przełomu wieku? Pol Arch Med Wewn. 2004; 111: 617-624.
2. OTC Statins: a bad decision for public health. Lancet. 2004; 363: 1659.
3. Davignon J, Mabile L Mechanisms of action of statins and their pleiotropic effects. Ann Endocrinol. 2001; 62: 101-112.
4. La Rosa JC. Pleiotropic effects of statins and their clinical significance. Am J Cardiol. 2001; 88: 291-293.
5. Goldstein JL, Brown MS. Regulation of the mevalone pathway. Nature. 1990; 343: 425-430.
6. Golberg AC. Clinical implications of statin event trials. Curr Atheroscler Rep. 2002; 4: 337-342.
7. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 360: 7-22.
8. Matru O, Laakso M, Isomäki H, et al. Cardiovascular mortality in patients with rheumatoid arthritis. Cardiology. 1989; 76: 71-77.
9. Alkaabi JK, et al. Rheumatoid arthritis and macrovascular disease. Rheumatology. 2003; 42: 292-297.
10. del Rincón ID, Williams K, Stern MP, et al. High incidence of cardiovascular events in rheumatoid arthritis cohort not explained by traditional risk factors. Arthritis Rheum. 2001; 44: 2737-2745.
11. Ross R. Atherosclerosis - an inflammatory disease. N Eng J Med. 1999; 340: 115-125.
12. Kaesemeyer WH, Cadlwell RB, Huang J, et al. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol. 1999; 33: 234-241.
13. Nickening G, Baumer AT, Temur Y, et al. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation. 1999; 100: 2131-2134.
14. Undas A, Brummel-Ziedins KE, Mann KE. Statins and blood coagulation. Artheroscler Thromb Vasc Biol. 2005; 25: 287-294.
15. Undas A, Celinska-Löwenhoff M, Domagała TB, et al. Early antithrombotic and antiinflammatory effectis of simvastatin versus fenofibrate in patients with hypercholesterolemia. Thromb Haemost. 2005; 94: 193-199.
16. Deakin S, Leviev I, Guernier S, et al. Simvastatin modulates expression of the PON1 gene and increases serum paraoxynase: a role for sterol regulatory element-blinding protein-2. Arteroscler Thromb Vasc Biol. 2003; 23: 2083-2089.
17. Kiechl S, Schett G, Wenning G, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circlation. 2004, 109: 2175-2180.
18. Celinska-Löwenhoff M, Löwenhoff T, Undas A, Gluszko P. Effects of hypolipemic drugs on the osteoprotegerin - sRANKL system in patients with coronary artery disease. Thromb Haemost. 2007; 97: 868-870.
19. MAAS investigators. Effects of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study Lancet. 1994; 344: 633-638.
20. Jukema JW, Bruschke AV, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. REGRESS. Circultion. 1995; 91: 2528-2540.
21. Salonen R, Nyyssonen K, Porkkala-Sarataho E, et al. The Kuopio Atherosclerosis Prevention Study: effects of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and etherosclerotic progression. Am J Cardiol. 1995; 76: C34-C39.
22. McCarey DW, McInnes IB, Madhok R, et al. Trial of Atorvastatin in Rhematoid Arthritis (TARA): double-blind randomized placebo-controlled trial. Lancet. 2004; 363: 2001-2002.
23. Nagashima T, Okazaki H, Yudoh K, et al. Apoptosis of rheumagoid synovial cells by statins through the bloking of protein geranylogeranylation. Arthritis and Rheum. 2006; 54: 579-586.
24. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprothein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002; 347: 1557-1565.
25. Albert MA, Glynn RJ, Ridker PM. Plasma concentration of C-reactive protein and the calculated Framingam Coronary Heart Disease Risk Score. Circulation. 2003; 108: 161-165.
26. Musiał J, Undas A, Gajewski P, et al. Anti-inflamatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol. 2001; 77: 247-253.
27. Zelvyte I, Dominaitiene R, Crisby M, et al. Modulation of inflammatory mediators and PPARγ and NFκB expression by pravastatin in response to lipoprotein in human monocytes in vitro. Pharmacol Res. 2002; 45: 147-154.
28. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antygen-1 by binding to a novel regulatory integrin site. Nat Med. 2001; 7: 687-692.
29. Noel B, Panizzon RG. Lupus-like syndrome associated with statin therapy. Dermatology. 2004; 208: 276-277.
30. Noel B, Panizzon RG. Atorvastatin-induced dematomyositis. Am J Med. 2001; 110: 670-671.
31. Graziadei IW, Obermoser GE, Sepp NT, et al. Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis. Lupus. 2003; 12: 409-412.
32. Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000; 6: 1004-1010.
33. Meier CR, Schlienger RG, Kraenzlin ME, et al. HMG-CoA reductase inhibitors and the risk of hip fractures. JAMA. 2000; 283: 3205-3210.
34. van Staa TP, Wegman S, Leufkens B, Cooper C. Use of statins and risk of fractures. JAMA. 2001; 286: 1850-1855.
35. The LIPID Study Group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet. 2002; 359: 1379-1387.
36. The Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344: 1383-1389.
37. Chan KA, Andrade SE, Boles M, et al. Inhibitors of hydroxymethyloglutaryl-coenzyme A reductase and risk of fractures among older women. Lancet. 2000; 355: 2185-2188.
38. Wang PS, Solomon DH, Mogun H, et al. HMG-CoA reductase inhibitors and the risk of hip fractures in elgerly patients. JAMA. 2000; 283: 3211-3216.
39. Rejnmark L, Olson ML, Johnsen SP, et al. Hip fracture risk in statin users: a population based, Danish case control study. Osteoporosis Int. 2004; 15: 452-458.
40. Women's Health Initiative Observational Study. JAMA. 2002; 288: 980-987.
41. Bauer DC, Mundy GR, Jamal SA, et al. Use of Statins and Fracture. Results of 4 Prospective Studies and Cumulative Meta-analysis of Observational Studies and Controlled Trials. Arch Intern Med. 2004; 26: 146-152.
42. Hatzigeorgiou C, Jackson JL. Hydroksymethyloglutaryl-coenzym A reductase inhibitors and osteoporosis: a meta-analysis. Osteoporosis Int. 2005; 16: 990-8.
43. McCarey DW, McInnes IB, Madhok R, et al. Trial of Atorvastatin in Rhematoid Arthritis (TARA): double-blind randomized placebo-controlled trial. Lancet. 2004; 363: 2001-2002.